Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion type Assertion NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_head.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion description "[In addition, Survivin-VISA-hEndoyCD plus 5-FC showed strong synergistic effects in combination with cisplatin in ovarian cancer cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_provenance.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion evidence source_evidence_literature NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_provenance.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion SIO_000772 22562248 NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_provenance.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion wasDerivedFrom befree-20150227 NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_provenance.
- NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_assertion wasGeneratedBy ECO_0000203 NP930852.RAk7nN_QgvQqT2zjNh3lWFFKZY10VovqEgzJKp0OrNRhs130_provenance.